Literature DB >> 21338664

Toxicology in the 21st century--working our way towards a visionary reality.

Ninna Berg1, Bart De Wever, Horst W Fuchs, Marianna Gaca, Cyrille Krul, Erwin L Roggen.   

Abstract

In November 2009 the In Vitro Testing Industrial Platform (IVTIP) organized a meeting entitled 'Toxicology in the 21st century--working our way towards a visionary reality'. Participating delegates included scientists, key opinion leaders, developers and users of 3Rs-related tests and testing strategies. This paper summarizes the discussions with respect to the conditions required to move the vision towards an applicable reality. It should not be considered as a comprehensive review of technologies that could be relevant for moving the in vitro testing and risk assessment field forward. Overall, the U.S. National Research Council (NRC) vision and strategy for toxicity testing in the 21st century was unanimously considered as the right approach to enable future toxicity testing without animal experimentation. Many elements of this vision were identified in the European initiatives aimed at the development of non-animal based methods. However, the need for concerted actions moving the current state-of-the-art towards a thorough, reliable and systematic approach to future toxicity testing was made evident by the discussions. Among the difficulties and hurdles on the way forward, the lack of physiologically relevant, metabolic competent and robust in vivo, ex vivo and in vitro models of both healthy and diseased people was frequently mentioned. In addition, there was a call for immediate implementation of emerging technologies and paradigms considered to be essential for transferring the vision into the reality of a toxicity-testing system assessing biologically significant perturbations in key pathways which are relevant for human biology. While the unique strengths of each of the available and emerging technologies was recognized, integration of available data and emerging technologies to integrated testing strategies (ITS) was highlighted as the preferred way forward. Method harmonization and standardization, as well as procedures and guidelines for putting together ITS, were urgently requested in order to facilitate proper implementation and acceptance. There was an urgent call for better coordination of the efforts that are ongoing or initiated in the 3Rs arena at national and international level. Education, training, communication and dissemination were addressed. It was recognised that the EPAA, through its 'Platform for Communication and Dissemination', has a very important and central role in this area.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21338664     DOI: 10.1016/j.tiv.2011.02.008

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  10 in total

1.  Carbon Nanotubes Induced Fibrogenesis on Nanostructured Substrates.

Authors:  Kai Wang; Xiaoqing He; Will Linthicum; Ryan Mezan; Liying Wang; Yon Rojanasakul; Qi Wen; Yong Yang
Journal:  Environ Sci Nano       Date:  2017-01-30

2.  Integrated testing strategies for safety assessments.

Authors:  Thomas Hartung; Tom Luechtefeld; Alexandra Maertens; Andre Kleensang
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

3.  Workshop report: Identifying opportunities for global integration of toxicogenomics databases, 26-27 June 2013, Research Triangle Park, NC, USA.

Authors:  Diana M Hendrickx; Rebecca R Boyles; Jos C S Kleinjans; Allen Dearry
Journal:  Arch Toxicol       Date:  2014-10-19       Impact factor: 5.153

Review 4.  GINIplus and LISAplus - Design and selected results of two German birth cohorts about natural course of atopic diseases and their determinants.

Authors:  J Heinrich; I Brüske; C Cramer; U Hoffmann; M Schnappinger; B Schaaf; A von Berg; D Berdel; U Krämer; I Lehmann; O Herbarth; M Borte; A Grübl; C P Bauer; C Beckmann; H Behrendt; J Ring; S Koletzko
Journal:  Allergol Select       Date:  2017-08-04

5.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products.

Authors:  Liam Simms; Fan Yu; Jessica Palmer; Kathryn Rudd; Edgar Trelles Sticken; Roman Wieczorek; Fiona Chapman; Lukasz Czekala; Matthew Stevenson; Grant O'Connell
Journal:  Front Toxicol       Date:  2022-02-16

6.  Allergic sensitization: screening methods.

Authors:  Gregory S Ladics; Jeremy Fry; Richard Goodman; Corinne Herouet-Guicheney; Karin Hoffmann-Sommergruber; Charlotte B Madsen; André Penninks; Anna Pomés; Erwin L Roggen; Joost Smit; Jean-Michel Wal
Journal:  Clin Transl Allergy       Date:  2014-04-15       Impact factor: 5.871

7.  A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes.

Authors:  Oscar T Suzuki; Amber Frick; Bethany B Parks; O Joseph Trask; Natasha Butz; Brian Steffy; Emmanuel Chan; David K Scoville; Eric Healy; Cristina Benton; Patricia E McQuaid; Russell S Thomas; Tim Wiltshire
Journal:  Front Genet       Date:  2014-08-29       Impact factor: 4.599

Review 8.  Adverse outcome pathway development from protein alkylation to liver fibrosis.

Authors:  Tomislav Horvat; Brigitte Landesmann; Alfonso Lostia; Mathieu Vinken; Sharon Munn; Maurice Whelan
Journal:  Arch Toxicol       Date:  2016-08-19       Impact factor: 5.153

9.  A framework for in vitro systems toxicology assessment of e-liquids.

Authors:  Anita R Iskandar; Ignacio Gonzalez-Suarez; Shoaib Majeed; Diego Marescotti; Alain Sewer; Yang Xiang; Patrice Leroy; Emmanuel Guedj; Carole Mathis; Jean-Pierre Schaller; Patrick Vanscheeuwijck; Stefan Frentzel; Florian Martin; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Toxicol Mech Methods       Date:  2016-04-26       Impact factor: 2.987

Review 10.  In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research.

Authors:  Eneko Madorran; Andraž Stožer; Sebastjan Bevc; Uroš Maver
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.